GlassScriptPhysician profile
Tia Bingham
NPI 1043645229
$1,720.71
in general payments reported to CMS, 2019-2025
27 companies · $60.74 in 2025
The $60.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2021: $218 · 2022: $38.85 · 2023: $571 · 2024: $670 · 2025: $60.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $386.67 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $135.38 | 2023-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $126.87 | 2021-2024 | Freestyle Libre 3, Eterna |
| Pfizer INC. | $125.32 | 2019-2025 | |
| Abbvie INC. | $118.56 | 2023-2024 | Qulipta |
| Amarin Pharma, INC. | $94.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $82.03 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $63.23 | 2023-2025 | Veozah |
| Boston Scientific Corporation | $57.85 | 2023-2025 | General - Pain Management |
| Janssen Pharmaceuticals, INC | $56.27 | 2024 | Spravato |
| Dexcom, INC. | $51.66 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.74 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $37.44 | 2023-2024 | |
| Ascensia Diabetes Care US INC. | $34.05 | 2023 | |
| Esperion Therapeutics, INC. | $33.31 | 2024 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.65 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $29.88 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $28.51 | 2023 | Mounjaro |
| Vanda Pharmaceuticals INC. | $28.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.84 | 2022 | |
| Dynavax Technologies Corporation | $24.18 | 2023 | Heplisav-B |
| Actelion Pharmaceuticals US, INC. | $21.61 | 2024 | Opsumit |
| Ironshore Pharmaceuticals INC. | $20.73 | 2019 | |
| Cequr Corporation | $18.75 | 2024 | Cequr Simplicity |
| Shield Therapeutics INC | $16.46 | 2023 | Accrufer |
| Neurocrine Biosciences, INC. | $15.48 | 2023 | Ingrezza |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tia Bingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.